Morgan Stanley Global Endurance Portfolio Class C MSJCX

Medalist Rating as of | See Morgan Stanley Investment Hub
  • NAV / 1-Day Return 21.51  /  −0.65 %
  • Total Assets 15.5M
  • Adj. Expense Ratio
    2.100%
  • Expense Ratio 2.100%
  • Distribution Fee Level Above Average
  • Share Class Type Level Load
  • Category Global Small/Mid Stock
  • Investment Style Small Blend
  • Min. Initial Investment 1,000
  • Status Open
  • TTM Yield 0.00
  • Turnover 176%

USD | NAV as of Jul 15, 2026 | 1-Day Return as of Jul 15, 2026, 12:11 AM GMT+0

Morningstar’s Analysis MSJCX

Will MSJCX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Morgan Stanley Global Endurance C holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings MSJCX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 51.8
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Roivant Sciences Ltd Ordinary Shares

8.73 1M
Healthcare

Victoria PLC

7.88 1M
Consumer Cyclical

QXO Inc

5.36 833,662
Industrials

Teleflex Inc

5.13 797,799
Healthcare

Immunovant Inc

4.66 724,459
Healthcare

Calumet Inc

4.65 723,636
Basic Materials

Arbutus Biopharma Corp

4.28 666,396
Healthcare

Appian Corp Class A

4.18 650,440
Technology

Floor & Decor Holdings Inc Class A

3.76 585,267
Consumer Cyclical

Royalty Pharma PLC Class A

3.18 494,235
Healthcare

Sponsor Center